TKNO Q2 2022 Earnings — Alpha Teknova, Inc. Revenue & Financial Results | Market Cap Arena

TKNOAlpha Teknova, Inc.

$133M

Q2 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$12M+40.6% YoY

Gross Profit

$5M44.9% margin

Operating Income

-$7M-56.7% margin

Net Income

-$6M-53.1% margin

EPS (Diluted)

$-0.22

QoQ Revenue Growth

+4.9%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$17M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$182M

Total Liabilities

$49M

Stockholders' Equity

$133M

Cash & Equivalents

$65M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$8M	+40.6%
Gross Profit	$5M	$3M	+56.4%
Operating Income	-$7M	-$3M	-162.3%
Net Income	-$6M	-$2M	-175.7%

Revenue Segments

Lab Essentials

$8M72%

Clinical Solutions

$3M25%

Other Product

$354,0003%

Geographic Segments

UNITED STATES

$11M97%

Non-US

$405,0003%